Brief: Blueprint Medicines Ayvakyt(Avapritinib) Receives European Commission Approval For Indolent Systemic Mastocytosis
12/12/2023 13:06
Dec 12 (Reuters) - Blueprint Medicines Corp BPMC.O :
* BLUEPRINT MEDICINES' AYVAKYT® (AVAPRITINIB) RECEIVES
EUROPEAN
COMMISSION APPROVAL AS THE FIRST AND ONLY TREATMENT FOR INDOLENT
SYSTEMIC MASTOCYTOSIS
Source text for Eikon: ID:nPn4KHCT5a
Further company coverage: BPMC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Blueprint Medicines
See all newsBrief: Sanofi Announces Extension Of Blueprint Tender Offer
Brief: Blueprint Medicines Announces Data Reinforcing Safety Profile Of Long-Term Ayvakit
U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, Circle
UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal
U.S. RESEARCH ROUNDUP-Biomea Fusion, GE Aerospace, P&G